Owens C W, Tomlinson B, Liu J B, Graham B R, Gillham C, Smith C C, Betteridge D J, Prichard B N
Department of Clinical Pharmacology, University College, London, UK.
J Hypertens Suppl. 1989 Dec;7(6):S320-1. doi: 10.1097/00004872-198900076-00156.
An extended dose-response study with xipamide, using seven doublings of the dose, from 0.3125 to 40 mg/day at 4-week intervals, was carried out in 12 hypertensive patients. Blood pressure showed a progressive decline with doses from 5 to 20 mg, and 40 mg xipamide produced no greater fall. Some subjects showed a maximum fall in blood pressure with a single dose increase but most showed a declining blood pressure over two or more dose increases. Plasma urea increased with doses of 5-40 mg to a similar extent, but there was no fall in the mean potassium level except with the 40-mg dose. Urinary calcium was reduced (from 4.2 to 1.7 mmol/24 h) on the 40-mg dose and the corrected plasma calcium level rose from 2.28 to 2.32 mmol/l. Triglycerides, very-low-density lipoprotein cholesterol and plasma aldosterone increased at the maximum dose; the cholesterol ratio, however, was unchanged.
对12名高血压患者进行了一项使用氯噻嗪的扩展剂量反应研究，剂量每隔4周倍增一次，从0.3125毫克/天增至40毫克/天。血压在5至20毫克剂量时呈逐渐下降趋势，40毫克氯噻嗪并未产生更大降幅。一些受试者单次增加剂量后血压降幅最大，但大多数受试者在两次或更多次增加剂量后血压呈下降趋势。血浆尿素在5至40毫克剂量时升高程度相似，但除40毫克剂量外，平均钾水平未下降。40毫克剂量时尿钙减少（从4.2降至1.7毫摩尔/24小时），校正后的血浆钙水平从2.28毫摩尔/升升至2.32毫摩尔/升。最大剂量时甘油三酯、极低密度脂蛋白胆固醇和血浆醛固酮增加；然而，胆固醇比值未变。
